Laurus Labs Limited announced on Tuesday that it has entered into a strategic partnership agreement with Global Fund for a period of 3.5 years for supply of AIDS drugs.
About Global Fund:
The Global Fund to Fight AIDS, Tuberculosis and Malaria is an international financing organization that aims to “attract, leverage and invest additional resources to end the epidemics of HIV/AIDS, tuberculosis and malaria to support attainment of the Sustainable Development Goals established by the United Nations.”
- This agreement Laurus Labs will have the volume commitments from the Global Fund for the treatment of HIV/AIDS.
- It has already received and executed the order from the global charity agency which would cater to the supples of the high burden diseases countries in Sub Saharan African(SSA) region.
- This is also the maiden order for Tenofovir/Lamivudine/Dolutegravir 300/300.50 mg(TLD) after the company has received a tentative approval from the US Food and Drug Administration(US FDA) in February.
Global Fund is a partnership between governments, civil society, the private sector and invests nearly $ 4 billion a year to support programmes designed to accelerate the end of AIDS, tuberculosis and malaria as epidemics.